Table 1.

Efficacy rate, toxicity rate, and hazard ratio for 2-dose and 3-dose scenariosa

Scenario2-dose
3-dose
0
1
2
0
1
2
3
Dose121212123123123123
Efficacy rate0.200.200.400.400.220.400.200.200.200.390.400.410.200.400.400.200.260.40
Toxicity rate0.300.300.130.290.130.260.300.300.300.110.280.300.110.180.300.240.250.30
Hazard ratio1.001.000.640.640.970.641.001.001.000.640.630.620.950.640.620.960.790.64
Scenario2-dose
3-dose
0
1
2
0
1
2
3
Dose121212123123123123
Efficacy rate0.200.200.400.400.220.400.200.200.200.390.400.410.200.400.400.200.260.40
Toxicity rate0.300.300.130.290.130.260.300.300.300.110.280.300.110.180.300.240.250.30
Hazard ratio1.001.000.640.640.970.641.001.001.000.640.630.620.950.640.620.960.790.64
a

Scenario 0 represents a null case where all doses are ineffective and thus has no optimal dose. In 2-dose scenarios, scenarios 1 and 2 represent the optimal doses are doses 1 and 2, respectively; and in 3-dose scenarios, scenarios 1-3 represent the optimal doses are doses 1-3, respectively. The optimal dose is indicated in boldface.

Table 1.

Efficacy rate, toxicity rate, and hazard ratio for 2-dose and 3-dose scenariosa

Scenario2-dose
3-dose
0
1
2
0
1
2
3
Dose121212123123123123
Efficacy rate0.200.200.400.400.220.400.200.200.200.390.400.410.200.400.400.200.260.40
Toxicity rate0.300.300.130.290.130.260.300.300.300.110.280.300.110.180.300.240.250.30
Hazard ratio1.001.000.640.640.970.641.001.001.000.640.630.620.950.640.620.960.790.64
Scenario2-dose
3-dose
0
1
2
0
1
2
3
Dose121212123123123123
Efficacy rate0.200.200.400.400.220.400.200.200.200.390.400.410.200.400.400.200.260.40
Toxicity rate0.300.300.130.290.130.260.300.300.300.110.280.300.110.180.300.240.250.30
Hazard ratio1.001.000.640.640.970.641.001.001.000.640.630.620.950.640.620.960.790.64
a

Scenario 0 represents a null case where all doses are ineffective and thus has no optimal dose. In 2-dose scenarios, scenarios 1 and 2 represent the optimal doses are doses 1 and 2, respectively; and in 3-dose scenarios, scenarios 1-3 represent the optimal doses are doses 1-3, respectively. The optimal dose is indicated in boldface.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close